An eight gene 'signature' can predict length of relapse-free survival in cancer patients after chemotherapy, according to a new research.
What does RFS stand for?
RFS stands for Relapse-Free Survival
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of RFS
We have 195 other meanings of RFS in our Acronym Attic
- Refeeding Syndrome
- Reference Flight System
- Reference Frame Selection (video coding)
- Referred in the Senate (bill status)
- Regardless of Feature Size (ANSI Y14.5M engineering drawings & related documentation practices)
- Regardless of Feature Size (geometric dimensioning and tolerancing)
- Registered Financial Specialist
- Registrar of Friendly Societies
- Règles Fondamentales de Sûreté (French: Fundamental Rules of Safety; nuclear power)
- Reiser File System (Unix file system)
Samples in periodicals archive:
A second phase II study from the MD Anderson Cancer Center concluded that the effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) is a highly effective regimen and has resulted in high rate of relapse-free survival in patients with newly diagnosed patients with core-binding factor AML.
Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT.
They examined local relapse-free survival, relapse-free survival and overall survival.
Looking at the medical records of 2,594 patients receiving chemotherapy for stage I and II breast cancer, researchers compared the relapse-free survival and overall survival among patients grouped by time from surgery to start of chemotherapy.
In a separate prospective analysis, the same researchers concluded that intermediate oncologic outcomes indicate LRP is a viable option for treating localized prostate cancer, and that worsening pathologic stage, prostate-specific antigen (PSA) level, Gleason sum, and margin status negatively affect biochemical relapse-free survival.
Twelve-year follow-up of a later trial that randomised 1,536 patients to tamoxifen alone or to tamoxifen with a chemotherapy mix of cyclophosphamide, methotrexate and 5-fluorouracil (CMFT) showed better relapse-free survival in the CMFT group (89% v 79%) and a higher overall survival (87% v 83%) although the latter difference was not statistically significant.
1989) also found that shorter patient delay was correlated with earlier staging of the disease, but interestingly found that there was an inverse relationship between patient delay and relapse-free survival.